• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:杨怡静,徐璐.三结构域蛋白33通过TGF-β1信号通路克服非小细胞肺癌奥希替尼获得性耐药[J].药学研究,2025,44(10):937-942,954[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1906次   下载 730次 本文二维码信息
码上扫一扫!
三结构域蛋白33通过TGF-β1信号通路克服非小细胞肺癌奥希替尼获得性耐药
杨怡静,徐璐
字体:加大+|默认|缩小-
(上海交通大学医学院药理学与化学生物学系,上海 200025)
摘要:
目的 研究三结构域蛋白33(tripartietemotif-containing33,TRIM33)在非小细胞肺癌(non-small cell lung cancer,NSCLC)奥希替尼(Osimertinib)获得性耐药的中的作用,并初步探究其作用机制。方法 通过浓度递增法构建对针对EGFR突变的三代靶向药物奥希替尼耐药的NSCLC耐药细胞H1975OR及HCC827OR细胞,CCK-8法检测耐药细胞对奥希替尼的IC50;Western blotting检测亲本细胞与耐药细胞中TRIM33的表达量变化;siRNA转染敲低亲本细胞中TRIM33的表达后,CCK-8法探究NSCLC细胞中TRIM33的表达量对奥希替尼敏感性的影响;初步探究其作用机制,通过ELISA和Western blotting验证TRIM33与转化生长因子-β1(transforming growth factor-β1,TGF-β1)的关系。结果 在NSCLC细胞对奥希替尼产生耐药后,耐药细胞内TRIM33的表达下降;通过siRNA敲低敏感细胞内TRIM33的表达后,细胞对奥希替尼的敏感性降低;进一步通过ELISA检测发现耐药细胞中TGF-β1分泌增加,亲本细胞在敲低TRIM33后TGF-β1的分泌增加,Western blotting结果显示耐药细胞中TGF-β1下游的SMAD信号通路被激活。结论 本文发现TRIM33通过抑制TGF-β1及其下游信号通路在EGFR突变型NSCLC克服获得性耐药的过程中起到重要作用,TRIM33有望成为EGFR突变型NSCLC中潜在的抗耐药靶点和预后标志物。
关键词:  三结构域蛋白33  非小细胞肺癌  获得性耐药  转化生长因子-β1
DOI:10.13506/j.cnki.jpr.2025.10.001
基金项目:上海市“科技创新行动计划”自然科学基金项目(No.24ZR1441900)
出版日期:2025-10-25
Triple domain protein 33 overcomes acquired resistance to osimertinib in non-small cell lung cancer through the TGF-β1 signaling pathway
YANG Yijing,XU Lu
(Department of Pharmacology and Chemical Biology, Shanghai Jiaotong University School of Medicine, Shanghai 200025,China)
Abstract:
Objective To investigate the role of tripartietemotif-containing 33 (TRIM33) in the acquired resistance to osimertinib in non-small cell lung cancer (NSCLC), and to explore its potential mechanism. Methods Using the concentration increasing method to construct H1975OR and HCC827OR NSCLC cells resistant to the third-generation targeted drug Osimertinib.CCK-8 assay was used to detect IC50 of the resistant cells. Western Blot was used to detect changes in TRIM33 expression levels between parental cells and drug-resistant cells. Knocking down TRIM33 by siRNA in parental cells and CCK-8 assay to investigate the effect of TRIM33 expression level on drug sensitivity. ELISA assay was used to explore the relationship between TRIM33 and the secretion of transforming growth factor-β1 (TGF-β1). Results After NSCLC cells acquired resistance to Osimertinib, the expression of TRIM33 in resistant cells significantly decreased. Knockdown of TRIM33 in sensitive cells decreased the sensitivity of cells to Osimertinib. ELISA assay revealed an increase in TGF-β1 secretion in drug-resistant cells, and knockdown of TRIM33 also increased the secretion of TGF-β1 in parental cells.Western blot showed that the SMAD signaling pathway downstream of TGF-β1 was activated in drug-resistant cells. Conclusion This study found that TRIM33 plays an important role in overcoming acquired resistance in NSCLC by inhibiting TGF-β1 and its downstream signaling pathways. TRIM33 is expected to become a potential anti-drug-resistance target and prognostic marker in NSCLC.
Key words:  Tripartietemotif-containing 33(TRIM33)  Non-small cell lung cancer  Acquired resistance  Transforming growth factor-β1
今日访问量:2486    总访问量:55338925
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司